Samuel Kintz, PRESIDENT AND CEO at Enliven Therapeutics, Inc. (ELVN), sold 4,540 shares at $27.56 ($125K) on 2024-07-31, disclosed to the SEC on 2024-08-02.
Scheduled sale ($125k) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $27.56 | 2,270 | $63K | 50.0% |
| 2 | $27.56 | 2,270 | $63K | 50.0% |
| Total | $27.56 avg | 4,540 | $125K | 100% |
| Filing → |
| ELVN | SELL | 2025-09-30 | $74K | — | Filing → |
| ELVN | SELL | 2025-09-25 | $56K | — | Filing → |
| ELVN | SELL | 2025-09-19 | $116K | — | Filing → |